Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
[PDF][PDF] Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - researchgate.net
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …
TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
[引用][C] P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum …
R Perez-Soler, A Chachoua, M Huberman, D Karp… - Lung Cancer, 2003 - infona.pl
P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with
advanced non-small cell lung cancer following failure of platinum-based chemotherapy × …
advanced non-small cell lung cancer following failure of platinum-based chemotherapy × …
[HTML][HTML] A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
HJM Groen, MA Socinski, F Grossi, E Juhasz… - Annals of oncology, 2013 - Elsevier
Background Combined inhibition of vascular, platelet-derived, and epidermal growth factor
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
[HTML][HTML] Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study
K Kubota, Y Nishiwaki, T Tamura, K Nakagawa… - Journal of Thoracic …, 2008 - Elsevier
Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …